Upfront Targeted Axillary Dissection and Sentinel Node Biopsy in Women Aged 45 and Older With Early ER Her2- Breast Cancer and Confirmed Nodal Metastases

What this Trial Is About

Researchers are investigating the recurrence rates and survival outcomes in women aged 45 and older with early-stage estrogen receptor-positive ER and Her2-negative invasive breast cancer who have biopsy-confirmed nodal disease detected by imaging. This phase II, prospective clinical trial focuses on patients undergoing upfront targeted axillary dissection TAD or sentinel node biopsy SNB followed by adjuvant therapy. Patient, tumor, and treatment data will be carefully documented throughout the study. Participants will receive breast surgery, either breast-conserving surgery BCS or lumpectomy or mastectomy, combined with TAD or SNB. Following surgery, they will undergo adjuvant radiation therapy as part of their treatment plan. This single-group study evaluates the outcomes of this treatment approach without comparison to other groups. Throughout the trial, participants will be monitored for regional and local recurrence rates, disease-free survival, breast cancer-specific survival, and overall survival over a 5-year period. Data collection will include patient and tumor characteristics as well as treatment details. The total study duration extends up to 7 years, with follow-up to assess long-term outcomes and survival.

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases